How Intelligencia supports teams navigating the oral GLP-1 shift We help clinical, portfolio, and BD leaders separate trend from overreach in a market moving at unprecedented speed: Clinical development teams use our benchmarks to compare phase progression, endpoint choices, and development velocity across oral vs injectable GLP-1 programshelping set realistic design and differentiation expectations
Semaglutide vs Tirzepatide: Does Food Guidance Change
Funding This article was supported by Novo Nordisk, who was provided with the opportunity to perform a medical accuracy review
When should I take BPC 157
00:21:16 Don Weinberger: Yeah
Following a median follow-up of 2.1 years, the risk of suffering a major cardiovascular adverse event (death, nonfatal AMI, nonfatal stroke or hospitalization for unstable angina) was similar in both the lixisenatide and the placebo arms (HR 1.02